The FDA has launched and is accepting applications for an Expedited Investigational New Drug (IND) Pilot aimed at speeding the path to first-in-human studies. The pilot is designed to reduce regulatory friction by partnering drug sponsors with qualified research institutions (QRI) that have established expertise to support efficient IND submissions. The agency says the program will accept applications through Oct. 30, 2026 and reflects “Operation Trialblazer,” a broader initiative to tighten timelines for early clinical development. FDA leadership also said feedback was incorporated into the pilot’s design. For biotech developers, the program could meaningfully shorten the iterative cycle between preclinical packages, manufacturing readiness, and the IND gate—especially for early assets where timing is a competitive differentiator.